KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

Autor: Mineur L, Lamy Pj, Evelyne Lopez-Crapez, Emptas H

Publikováno v: British Journal of Cancer

Background: KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E mutation has been associated with resistance. Additional KRAS mutations are described in CRC.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5831ff2d5edb67d4c58ca1727eaccf98
https://pubmed.ncbi.nlm.nih.gov/19603018

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Vestigial retrorectal cyst in adults].

Autor: Godlewski G; Département de chirurgie digestive et de cancérologie digestive, hôpital Carémeau, CHU, rue du Professeur-Robert-Debré, 30900 Nîmes, France., Philippe O, Ould Said H, Prudhomme M, Poilleux J, Pignodel C, Emptas H

Publikováno v: Annales de chirurgie [Ann Chir] 2000 Nov; Vol. 125 (9), pp. 844-9.